RVTY vs ILMN vs TECH Stock Comparison

Revvity, Illumina and Bio-Techne Prices as of Oct 28, 2026 Peers: Industry group
1 more company in this comparison (TMO) Create a free account to keep reading and compare up to 10 companies.
RVTY Revvity, Inc.
$165.36 +9.5% 1M +71.4% 1Y
Market cap
$18.45B
P/E
77.7x
Revenue (TTM)
$2.91B
Div. yield
0.17%
Life Sciences Tools Healthcare
3 wins
ILMN Illumina, Inc.
$288.79 +6.2% 1M +195.3% 1Y
Market cap
$43.61B
P/E
52.9x
Revenue (TTM)
$4.49B
Div. yield
–
Life Sciences Tools Healthcare
6 wins
TECH BIO-TECHNE Corp
$72.69 +0.2% 1M +13.7% 1Y
Market cap
$11.35B
P/E
62.3x
Revenue (TTM)
$1.22B
Div. yield
0.44%
Life Sciences Tools Healthcare
3 wins

Head to Head

12 decided of 12

Illumina leads on 6 of the 12 questions below (Illumina 6, Revvity 3, Bio-Techne 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionRVTYILMNTECHLeader
Larger companyMarket capitalisation $18.45B $43.61B $11.35B ILMN
Cheaper on earningsLower P/E, profitable companies only 77.7x 52.9x 62.3x ILMN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 32.4x 57.9x 33.7x RVTY
Faster revenue growthRevenue growth, trailing twelve months +4.1% +4.9% -0.4% ILMN
More profitableNet margin, trailing twelve months 8.2% 18.4% 15.0% ILMN
Better return on capitalReturn on invested capital 3.1% 15.1% 8.3% ILMN
Less leveragedLower net debt / EBITDA 2.8x 0.7x -0.2x TECH
Higher dividend yieldTrailing dividend yield 0.17% — 0.44% TECH
Better 1-year returnPrice return, last 12 months +71.4% +195.3% +13.7% ILMN
Better 5-year returnAnnualised price return, 5 years -1.3%/yr -6.5%/yr -11.1%/yr RVTY
Less volatileAnnualised volatility, 1 year 39.9% 50.4% 43.5% RVTY
Higher overall scoreMean of the five percentile scores vs peers 58/100 65/100 66/100 TECH

Percentile Scorecard

RVTYILMNTECH

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisRVTYILMNTECH
Valuation 68 #74 of 227 50 #115 of 227 59 #94 of 227
Growth 28 #158 of 219 46 #119 of 219 40 #131 of 219
Profitability 80 #41 of 205 97 #8 of 205 94 #14 of 205
Financial Health 47 #127 of 237 51 #116 of 237 87 #32 of 237
Shareholder Returns 66 #46 of 135 83 #24 of 135 52 #66 of 135
Overall 58 65 66
  • RVTY ranked among 247 companies in Medical Devices and Diagnostics
  • ILMN ranked among 247 companies in Medical Devices and Diagnostics
  • TECH ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodRVTYILMNTECHSPY
1 month +9.5%+6.2%+0.2% +0.9%
3 months +45.8%+48.2%+0.9% +5.9%
6 months +101.0%+139.9%+39.9% +8.5%
Year to date +70.9%+120.2%+23.6% +13.3%
1 year +71.4%+195.3%+13.7% +12.4%
3 years +69.0%+171.8%+22.1% +88.1%
3 years, per year +19.1%+39.6%+6.9% +23.5%
5 years -6.5%-28.5%-44.5% +68.2%
5 years, per year -1.3%-6.5%-11.1% +11.0%
10 years +225.5%+114.2%+187.8% +263.4%
10 years, per year +12.5%+7.9%+11.2% +13.8%

Risk

MeasureRVTYILMNTECHSPY
Volatility, 1Y 39.9%50.4%43.5% 12.7%
Downside volatility, 1Y 35.9%39.0%43.6% 12.7%
Beta vs S&P 500, 1Y 1.230.830.77 1.00
Return / volatility, 1Y 1.793.880.31 0.98
Max drawdown, 5Y -59.2%-82.9%-67.0% -25.4%
From 52-week high 0.0%-1.7%0.0% -0.9%
52-week high $165.36$293.69$72.69 $779.14
52-week low $82.26$95.03$43.30 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleRVTYILMNTECH
P/E now vs peer median 77.7xmedian 28.8x 52.9xmedian 28.8x 62.3xmedian 28.8x
P/S now vs peer median 6.3xmedian 3.0x 9.7xmedian 3.0x 9.3xmedian 3.0x
EV/EBITDA now vs peer median 26.6xmedian 17.4x 38.5xmedian 17.4x 32.3xmedian 17.4x
P/FCF now vs peer median 32.4xmedian 25.7x 46.8xmedian 25.7x 43.1xmedian 25.7x
P/B now vs peer median 2.6xmedian 2.4x 15.4xmedian 2.4x 5.4xmedian 2.4x
PEG now vs peer median -2.49median 1.03 1.75median 1.03 -4.77median 1.03

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsRVTYILMNTECH
Revenue $2.91B $4.49B $1.22B
Gross profit $1.60B $2.98B $799.07M
Operating income $358.85M $882.00M $251.89M
Net income $237.55M $825.00M $181.86M
Free cash flow $568.85M $931.00M $263.22M
R&D $215.83M $960.00M $94.77M
EPS (diluted) $2.13 $5.39 $1.16
Cash & equivalents $1.02B $1.04B $264.71M
Total debt $3.21B $1.99B $200.00M
Shares (diluted) 111.63M 153.00M 157.01M
Enterprise value $14.72B $38.37B $10.55B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricRVTYILMNTECH
P/E 77.7x 52.9x 62.3x
P/FCF 32.4x 46.8x 43.1x
P/Operating cash flow 28.9x 39.8x 38.8x
P/S 6.3x 9.7x 9.3x
P/B 2.6x 15.4x 5.4x
P/Tangible book 3.7x 18.0x 6.3x
EV/EBITDA 26.6x 38.5x 32.3x
EV/EBIT 57.5x 50.4x 44.8x
EV/Revenue 7.1x 9.9x 9.3x
EV/FCF 36.3x 47.7x 42.9x
EV/Operating cash flow 32.3x 40.6x 38.6x
PEG (3Y EPS CAGR) -2.49 1.75 -4.77

Growth

14 metrics
MetricRVTYILMNTECH
Revenue growth (1Y) 4.1% 4.9% -0.4%
Revenue CAGR (3Y) 0.9% -1.0% 2.2%
Gross profit growth (1Y) 2.3% 4.6% 1.1%
Gross profit CAGR (3Y) -0.4% 2.9% 1.3%
Operating income growth (1Y) -5.5% -31.8% 146.3%
Operating income CAGR (3Y) -3.7% 28.3% -5.5%
Net income growth (1Y) -16.7% -34.4% 147.8%
Net income CAGR (3Y) -33.8% 30.0% -14.0%
EPS growth (1Y) -12.3% -32.7% 152.0%
EPS CAGR (3Y) -31.2% 30.1% -13.1%
Operating cash flow growth (1Y) 6.2% -5.1% 1.6%
Operating cash flow CAGR (3Y) 86.9% 38.1% 4.7%
Free cash flow growth (1Y) 9.5% -9.7% 2.6%
Free cash flow CAGR (3Y) 64.8% 105.0% 6.8%

Profitability

14 metrics
MetricRVTYILMNTECH
Gross margin 55.0% 66.4% 65.8%
EBITDA margin 26.6% 25.7% 28.7%
Operating margin 12.3% 19.6% 20.7%
Pretax margin 9.0% 22.6% 19.8%
Net margin 8.2% 18.4% 15.0%
FCF margin 19.5% 20.7% 21.7%
Operating cash flow margin 21.9% 24.4% 24.0%
Return on equity 3.3% 29.9% 8.7%
Return on assets 2.0% 12.5% 7.1%
Return on invested capital 3.1% 15.1% 8.3%
Return on capital employed 3.3% 17.5% 10.5%
Asset turnover 0.2x 0.7x 0.5x
Cash conversion (OCF / net income) 2.7x 1.3x 1.6x
Stock comp / revenue 0.8% 5.9% 0.5%

Financial Health

11 metrics
MetricRVTYILMNTECH
Debt / assets 26.6% 29.9% 7.7%
Debt / equity 0.4x 0.7x 0.1x
Net debt / EBITDA 2.8x 0.7x -0.2x
Debt / FCF 5.6x 2.1x 0.8x
Liabilities / assets 40.0% 57.3% 18.5%
Equity / assets 60.0% 42.7% 81.5%
Interest coverage 3.7x 8.9x 26.2x
Current ratio 1.8x 1.8x 4.5x
Quick ratio 1.4x 1.2x 2.9x
Cash ratio 0.8x 0.7x 1.6x
Altman Z-score 3.45 8.19 15.91

Shareholder Returns

7 metrics
MetricRVTYILMNTECH
Dividend yield 0.2% – 0.4%
Net buyback yield 2.5% 1.2% -0.3%
Shareholder yield 2.7% 1.2% 0.1%
Payout ratio (earnings) 13.4% – 27.4%
Payout ratio (FCF) 5.6% – 19.0%
Dividend growth (1Y) -6.3% – -0.9%
Dividend CAGR (3Y) -6.1% – -0.2%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusRVTYILMNTECH
Forward P/E 32.4xFY2026 57.9xFY2026 33.7xFY2027
EPS, next fiscal year $5.10FY2026 $4.99FY2026 $2.16FY2027
EPS growth, next FY +0.8%FY2026 +3.1%FY2026 +11.9%FY2027
EPS growth, the year after +11.0% +25.7% +5.1%
Revenue, next fiscal year $2.98BFY2026 $4.52BFY2026 $1.19BFY2027
Revenue growth, next FY +4.0%FY2026 +4.1%FY2026 -2.1%FY2027
Revenue growth, the year after -2.0% +12.0% +13.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersRVTYILMNTECH
Held by institutions 100.0% 100.0% 100.0%
Institutions holding 545 933 597
Change in shares held, QoQ -1.3% +0.0% -0.6%
Institutions buying 301 463 293
Institutions selling 161 330 241
Buyers to sellers 1.87 1.40 1.22

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

RVTYILMNTECH
RVTY 1.00 0.51 0.45
ILMN 0.51 1.00 0.22
TECH 0.45 0.22 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, RVTY, ILMN and TECH?

Illumina (ILMN) is the largest by market capitalisation: Revvity (RVTY) $18.45B, Illumina (ILMN) $43.61B, Bio-Techne (TECH) $11.35B.

Which stock is cheaper, RVTY, ILMN and TECH?

Illumina (ILMN) trades on the lowest price-to-earnings ratio (Revvity (RVTY) 77.7x, Illumina (ILMN) 52.9x, Bio-Techne (TECH) 62.3x). On next year's consensus earnings, Revvity (RVTY) is cheapest (Revvity (RVTY) 32.4x, Illumina (ILMN) 57.9x, Bio-Techne (TECH) 33.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Illumina (ILMN) grew revenue fastest over the trailing twelve months: Revvity (RVTY) +4.1%, Illumina (ILMN) +4.9%, Bio-Techne (TECH) -0.4%.

Which company is more profitable?

Illumina (ILMN) has the highest net margin (Revvity (RVTY) 8.2%, Illumina (ILMN) 18.4%, Bio-Techne (TECH) 15.0%). On return on invested capital, Illumina (ILMN) leads (Revvity (RVTY) 3.1%, Illumina (ILMN) 15.1%, Bio-Techne (TECH) 8.3%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Revvity (RVTY) +71.4%, Illumina (ILMN) +195.3%, Bio-Techne (TECH) +13.7%. Over five years, Revvity (RVTY) compounded fastest (Revvity (RVTY) -1.3%/yr, Illumina (ILMN) -6.5%/yr, Bio-Techne (TECH) -11.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Bio-Techne (TECH) has the highest dividend yield: Revvity (RVTY) 0.17%, Bio-Techne (TECH) 0.44%. Illumina (ILMN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Revvity (RVTY) has been the steadiest (Revvity (RVTY) 39.9%, Illumina (ILMN) 50.4%, Bio-Techne (TECH) 43.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, RVTY, ILMN and TECH?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Illumina (ILMN) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.